Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease

Current Gastroenterology Reports

Volumn 8, Issue 6, 2006, Pages 499-505

  Nguyen, Geoffrey C ^b   Harris, Mary L ^b   Dassopoulos, Themistocles ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALLOPURINOL; ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLSALAZINE; PLACEBO; PREDNISONE; TACROLIMUS; TIOGUANINE;

ADJUVANT THERAPY; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COLON RESECTION; COMBINATION CHEMOTHERAPY; CONGENITAL MALFORMATION; CROHN DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; LIVER TOXICITY; LOW DRUG DOSE; MAINTENANCE THERAPY; META ANALYSIS; MONOTHERAPY; NEOPLASM; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PREGNANCY; QUALITY ADJUSTED LIFE YEAR; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; T CELL LYMPHOMA; TERATOGENICITY; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TREATMENT OUTCOME;

EID: 33845895292     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-006-0040-6     Document Type: Review

References (53)

1. D'Haens GR, Hommes D, Baert F, et al.: A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease. Gastroenterology 2006, 130:A110.
2. Hommes D, Baert F, van Assche G, et al.: The ideal management of Crohn's disease: top down versus step up strategies, a randomized controlled trial. Gastroenterology 2006, 130:A108.
3. Poppe D, Tiede I, Fritz G, et al.: Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006, 176:640-51.
4. Lichtenstein GR, Abreu MT, Cohen R, et al.: American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:940-987.
5. Ardizzone S, Maconi G, Russo A, et al.: Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006, 55:47-53.
6. Hanauer SB, Korelitz BI, Rutgeerts P, et al.: Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004, 127:723-729.
7. Ardizzone S, Maconi G, Sampietro GM, et al.: Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004, 127:730-740.
8. Cosnes J, Nion-Larmurier I, Beaugerie L, et al.: Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005, 54:237-241.
9. Dubinsky MC: Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2004, 2:731-743.
10. Lichtenstein GR, Abreu MT, Cohen R, et al.: American Gastroenterological Association Institute medical position statement on cortico steroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:935-939.
11. Cuffari C, Dassopoulos T, Turnbough L, et al.: Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004, 2:410-417.
12. Sparrow MP, Hande SA, Friedman S, et al.: Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005, 22:441-446.
13. Sparrow M, Hande SA, Friedman S, et al.: Optimization of 6-thioguanine production by allopurinol in inflammatory bowel disease patients not responding to azathioprine/6-mercaptopurine leads to improved disease activity, reduced corticosteroid requirements and normalization of liver enzymes. Gastroenterology 2006, 130:A142.
14. Teml A, Schwab M, Harter M, et al.: A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis. Scand J Gastroenterol 2005, 40:1205-1213.
15. Dubinsky MC, Vasiliauskas EA, Singh H, et al.: 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003, 125:298-303.
16. Osterman MT, Kundu R, Lichtenstein GR, et al.: Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006, 130:1047-1053.
17. Neurath MF, Kiesslich R, Teichgraeber U, et al.: Prediction of azathioprine responsiveness in Crohn's disease by 6-thioguanosine di- and triphosphate levels in red blood cells: a prospective study. Gastroenterology 2006, 130:A84.
18. Lemann M, Mary JY, Colombel JF, et al.: A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005, 128:1812-1818.
19. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2005, CD003459.
20. Ardizzone S, Bollani S, Manzionna G, et al.: Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis 2003, 35:619-627.
21. van Dieren JM, Kuipers EJ, Samsom JN, et al.: Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis 2006, 12:311-327.
22. Herrlinger KR, Cummings JR, Barnardo MC, et al.: The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet Genomics 2005, 15:705-711.
23. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992, 13:136-142.
24. Lichtiger S, Present DH, Kornbluth A, et al.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841-1845.
25. D'Haens G, Lemmens L, Geboes K, et al.: Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001, 120:1323-1329.
26. van Assche G, D'Haens G, Noman M, et al.: Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003, 125:1025-1031.
27. McDonald JW, Feagan BG, Jewell D, et al.: Cyclosporine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2005, CD000297.
28. Ogata H, Matsui T, Nakamura M, et al.: A randomised, dose-finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006, 55:1255-1262.
29. Sandborn WJ, Present DH, Isaacs KL, et al.: Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003, 125:380-388.
30. Baumgart DC, Pintoffl JP, Sturm A, et al.: Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease: a longterm follow-up. Am J Gastroenterol 2006, 101:1048-1056.
31. Neurath MF, Wanitschke R, Peters M, et al.: Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 1999, 44:625-628.
32. Orth T, Peters M, Schlaak JF, et al.: Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000, 95:1201-1207.
33. Farrell RJ, Alsahli M, Jeen YT, et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003, 124:917-924.
34. Lemann M, Mary JY, Duclos B, et al.: Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006, 130:1054-1061.
35. Hanauer SB, Feagan BG, Lichtenstein GR, et al., for the ACCENT I Study Group: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
36. Maini RN, Breedveld FC, Kalden JR, et al.: Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004, 50:1051-1065.
37. van Assche G, Paintaud G, D'HG, et al.: Continuation of immunomodulators is not required to maintain adequate infliximab efficacy in patients with Crohn's disease but may improve pharmacokinetics. Gastroenterology 2006, 130:A142.
38. Panaccione R, Hanauer SB, Fedorak R, et al.: Concomitant immunosuppressive and adalimumab therapy in patients with Crohn's disease. Gastroenterology 2006, 130:A479.
39. Mantzaris GJ, Sfakianakis M, Archavlis E, et al.: A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004, 99:1122-1128.
40. Hande S, Wilson-Rich N, Bousvaros A, et al.: 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis 2006, 12:251-257.
41. Kandiel A, Fraser AG, Korelitz BI, et al.: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54:1121-1125.
42. Disanti W, Rajapakse RO, Korelitz BI, et al.: Incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6-mercaptopurine for inflammatory bowel disease. Clin Gastroenterol Hepatol 2006, 4:1025-1029.
43. Lewis JD, Schwartz JS, Lichtenstein GR: Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000, 118:1018-24.
44. Navarro JT, Ribera JM, Mate JL, et al.: Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lympboma 2003, 44:531-533.
45. Thayu M, Markowitz JE, Mamula P, et al.: Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005, 40:220-222.
46. Lichtenstein GR, Cohen RD, Feagan BG, et al.: Safety of infliximab and other Crohn's disease therapies - TREAT registry data with nearly 15,000 patient-years of follow-up. Gastroenterology 2006, 130, 4(Supp2): A71.
47. Kane SV, Khatibi B, Reddy D: Use of immunosuppressants results in a higher incidence of abnormal Pap smears in women with inflammatory bowel disease (IBD). Gastroenterology 2006, 130:A2.
48. Colombel JF, Loftus EV, Jr, Tremaine WJ, et al.: Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004, 99:878-883.
49. Subramanian V, Pollok RC, Kang JY, et al.: Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg 2006, 93:793-799.
50. Norgard B, Pedersen L, Fonager K, et al.: Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol Ther 2003, 17:827-834.
51. Francella A, Dyan A, Bodian C, et al.: The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003, 124:9-17.
52. Bar OB, Hackman R, Einarson T, et al.: Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001, 71:1051-1055.
53. Baumgart DC, Sturm A, Wiedenmann B, et al.: Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut 2005, 54:1822-1823.